|Articles|October 7, 2021
Supplements and Featured Publications
- Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease
Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease
Advertisement
This publication was funded and developed by United Therapeutics.
This AJMC® Clinical Brief summarizes results of the pivotal study by Aaron Waxman MD, PhD, et al published in The New England Journal of Medicine on the safety and efficacy of inhaled treprostinil in patients with pulmonary hypertension due to interstitial lung disease.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
TrumpRx Launch Brings Savings—and Uncertainty
2
How Do GLP-1 Agonists Fit Into Stroke Care?
3
Addressing Disparities at Every Step of the Stroke Care Pathway: Luke Messac, MD, PhD
4
Aligning Treatment Goals in IgA Nephropathy: Applying KDIGO’s Dual-Pathway Framework to Clinical Decision-Making
5
